expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s
Business Operations summarized as follows: 1. The Consolidated Financial Statements 1.1 Report and analysis of Business Operations Revenue Revenue from operations Revenue from operations for the Company and
Result of Business Operations summarized as follows: 1. The Consolidated Financial Statements 1.1 Report and analysis of Business Operations Revenue Revenue from operations Revenue from operations for the
Result of Business Operations are summarized as follows: 1. The Consolidated Financial Statements 1.1 Report and analysis of Business Operations Revenue Revenue from operations Revenue from operations for
MARCH 31, 2018 1. Analysis of operation results for the fir st quarter of 2018 in compar ison with those for the same quar ter of 2017 (from the consolidated financial statements) Items First quarter of
: Million Baht) Consolidated financial statements Q2’ 2020 Q2’ 2019 % Change Sales and Service Income 333 511 -35 Other Revenue 8 4 100 Less Cost of Sales and Services 276 412 -33 Selling and Administrative
fixed interest rate from 2.05 to 3.01 percent per annum to reduce financial cost and risk management from floating interest rate. As a result, the Company has saved interest expense approximately by Baht
2,451 44 1.8 Selling and administrative expenses 305 312 (7) -2.2 Total expenses 2,800 2,763 37 1.3 Profit from operating activities 1,089 1,362 (273) -20.0 Finance cost 379 305 74 24.3 Interest expense
) -34.6 Cost of service 2,591 2,393 198 8.3 Selling and administrative expenses 303 276 27 9.8 Finance cost 328 312 16 5.1 Interest expense from the MRT Purple Line Project 94 108 (14) -13.0 Total expenses